[關(guān)鍵詞]
[摘要]
目的 研究復(fù)方丹參片聯(lián)合胸腺法新治療失代償期丙型肝炎肝硬化的臨床療效。方法 選取2013年10月-2014年5月中國(guó)石油天然氣集團(tuán)公司中心醫(yī)院和首都醫(yī)科大學(xué)附屬北京佑安醫(yī)院收治的失代償期丙型肝硬化患者120例,隨機(jī)分為對(duì)照組和治療組,每組各60例。對(duì)照組靜脈注射注射用胸腺法新,1.6 mg/次,2次/周;治療組在對(duì)照組基礎(chǔ)上口服復(fù)方丹參片,3片/次,3次/d。兩組患者均持續(xù)治療12個(gè)月。評(píng)價(jià)兩組患者臨床效果,同時(shí)比較兩組患者治療前后肝功能指標(biāo)、肝纖維化指標(biāo)、丙型肝炎病毒RNA(HCV-RNA)水平、Child-Pugh評(píng)分和乙型肝炎E抗原(HBeAg)轉(zhuǎn)陰率變化。結(jié)果 治療12個(gè)月后,兩組患者總膽紅素(TBiL)、丙氨酸氨基轉(zhuǎn)移酶(ALT)水平均顯著下降,白蛋白(ALB)水平顯著上升,同組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組患者血漿TBiL、ALT和ALB下降水平顯著優(yōu)于對(duì)照組(P<0.05)。治療12個(gè)月后,兩組患者透明質(zhì)酸(HA)、Ⅲ型前膠原(PCIII)和層黏連蛋白(LN)水平均顯著下降(P<0.05);且治療組患者HA、PCIII和LN水平顯著比對(duì)照組低(P<0.05)。治療12個(gè)月后,治療組患者HCV-RNA顯著低于治療前,治療組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且低于治療12個(gè)月后對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療12個(gè)月后,治療組患者Child-Pugh評(píng)分顯著降低,兩組HBeAg轉(zhuǎn)陰率顯著升高,同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組患者Child-Pugh評(píng)分和HBeAg轉(zhuǎn)陰率改善情況明顯優(yōu)于對(duì)照組(P<0.05)。結(jié)論 復(fù)方丹參片聯(lián)合胸腺法新治療失代償期肝硬化患者臨床效果良好,肝纖維化指標(biāo)、肝功能以及病毒學(xué)指標(biāo)均得到了顯著改善,緩解了患者的臨床癥狀。
[Key word]
[Abstract]
Objective To study the clinical effect of Compound Danshen Tablets combined with Thymalfasin for injection in treatment of decompensated hepatitis C cirrhosis. Methods Patients (120 cases) with decompensated hepatitis C cirrhosis in CNPC Central Hospital and Beijing You'an Hospital, Capital Medical University from October 2013 to May 2014 were divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Thymalfasin for injection, 1.6 mg/time, twice one week. Patients in the treatment group were po administered with Compound Danshen Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 12 months. After treatment, the clinical efficacy was evaluated, liver function and fibrosis indexes, HCV-RNA level, Child-Pugh score and HBeAg negative conversion rate in two groups before and after treatment were compared. Results After treatment for 12 months, TBiL and ALT levels in two groups were significantly decreased, but ALB level was increased, the difference was statistically significant in the same group (P<0.05). And the TBiL, ALT, and ALB levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment for 12 months, the HA, PCIII, and LN levels in two groups were significantly decreased (P<0.05). And the HA, PCIII, and LN levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment for 12 months, HCV-RNA level in the treatment was significantly decreased, and which was lower than that in the control group after treatment, and there were differences in the treatment group and between two groups after treatment (P<0.05). After treatment for 12 months, Child-Pugh score in the treatment group was significantly decreased, HBeAg negative conversion rate in two groups was significantly increased, and the difference was statistically significant in the same group (P<0.05). The Child-Pugh score and HBeAg negative conversion rate in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Compound Danshen Tablets combined with Thymalfasin for injection has a good clinical effect in treatment of decompensated hepatitis C cirrhosis, can significantly improve liver fibrosis, liver function and virology indicators, and relieve the clinical symptoms.
[中圖分類號(hào)]
[基金項(xiàng)目]